Tralokinumab’s Track Record in Older Adults With Atopic Dermatitis
In a post-hoc analysis of 75 older adults, tralokinumab (Adbry) was safe, well tolerated, and efficacious in treating moderate-to-severe atopic dermatitis (AD). A brief report describing the findings of the post-analysis appeared recently in .